Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Unscheduled Visit Galafold (migalastat) AT1001-012 NCT01218659

- 11/11/16 - 1 formulario, 16 itemgroups, 38 items, 1 idioma

Itemgroups: Date of visit, 12 Lead ECG, Hematology/Coagulation, clinically significant abnormal laboratory values Hematology, Chemistry, Laboratory findings, clinically significant abnormal laboratory values Chemistry, Urinanalysis, clinically significant abnormal laboratory values Urinalysis, 24-Hr Urine Collection, Additional Observations, Vital Signs 2, GFR of Iohexol, Echocardiography, Brain MRI, Physical Examination, Unscheduled Visit

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Unscheduled Visit

Visit 14 Galafold (migalastat) AT1001-012 NCT01218659

- 11/11/16 - 1 formulario, 12 itemgroups, 30 items, 1 idioma

Itemgroups: Date of visit, 12 Lead ECG, Hematology/Coagulation, clinically significant abnormal laboratory values Hematology, Chemistry, Laboratory findings, clinically significant abnormal laboratory values Chemistry, Urinanalysis, clinically significant abnormal laboratory values Urinalysis, Additional Observations, Vital Signs 2, Secondary Endpoint Criteria, Physical Examination

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Visit 14

Study Completion Study Galafold (migalastat) AT1001-012 NCT01218659

- 11/11/16 - 1 formulario, 3 itemgroups, 7 items, 1 idioma

Itemgroups: Additional Observations, Study Completion, Casebook Signature

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Study Completion

Concomitant Medications Galafold (migalastat) AT1001-012 NCT01218659

- 11/11/16 - 1 formulario, 3 itemgroups, 10 items, 1 idioma

Itemgroups: Additional Observations, Prior/Concomitant Medications, application of medication

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Concomitant Medications

System Screening Galafold (migalastat) AT1001-012 NCT01218659

- 11/11/16 - 1 formulario, 1 itemgroup, 3 items, 1 idioma

Itemgroup: System Screening

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT System Screening

Visit 13 Galafold (migalastat) AT1001-012 NCT01218659

- 11/11/16 - 1 formulario, 17 itemgroups, 44 items, 1 idioma

Itemgroups: Date of visit, 12 Lead ECG, Hematology/Coagulation, clinically significant abnormal laboratory values Hematology, Chemistry, Laboratory findings, clinically significant abnormal laboratory values Chemistry, Urinanalysis, clinically significant abnormal laboratory values Urinalysis, 24-Hr Urine Collection, Additional Observations, Vital Signs 2, GFR of Iohexol, Echocardiography, SF-36 Health Survey, Modified Brief Pain Inventory, Secondary Endpoint Criteria, Physical Examination

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Visit 13

Early Termination Galafold (migalastat) AT1001-012 NCT01218659

- 11/11/16 - 1 formulario, 19 itemgroups, 65 items, 1 idioma

Itemgroups: Date of visit, 12 Lead ECG, Hematology/Coagulation, clinically significant abnormal laboratory values Hematology, Chemistry, Laboratory findings, clinically significant abnormal laboratory values Chemistry, Urinanalysis, clinically significant abnormal laboratory values Urinalysis, 24-Hr Urine Collection, Additional Observations, Vital Signs 2, GFR of Iohexol, Echocardiography, SF-36 Health Survey, Modified Brief Pain Inventory, Secondary Endpoint Criteria, Enzyme Replacement Therapy, Drug log, Physical Examination

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Early Termination

Drug Accountability for Optional Open-Label Extension Galafold (migalastat) AT1001-012 NCT01218659

- 11/11/16 - 1 formulario, 2 itemgroups, 15 items, 1 idioma

Itemgroups: Additional Observations , Drug Accountability for Optional Open-Label Extension

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Drug Accountability for Optional Open-Label Extension

Follow-up Galafold (migalastat) AT1001-012 NCT01218659

- 11/11/16 - 1 formulario, 12 itemgroups, 30 items, 1 idioma

Itemgroups: Date of visit, 12 Lead ECG, Hematology/Coagulation, clinically significant abnormal laboratory values Hematology, Chemistry, Laboratory findings, clinically significant abnormal laboratory values Chemistry, Urinanalysis, clinically significant abnormal laboratory values Urinalysis, Additional Observations, Vital Signs 2, Secondary Endpoint Criteria, Physical Examination

A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Follow-up